Distinguished in Astrocytoma

Luc Taillandier

CHRU Nancy
Nancy, FR 
Distinguished in Astrocytoma
CHRU Nancy
Nancy, FR 
OverviewLocationsClinical Research

Overview

Luc Taillandier practices in Nancy, France. Mr. Taillandier is rated as a Distinguished expert by MediFind in the treatment of Astrocytoma. His top areas of expertise are Glioma, Gliomatosis Cerebri, Brain Tumor, and Glioblastoma.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 16 articles in the study of Astrocytoma.

Gender
Male

Locations

CHRU Nancy
Nancy, 54000, France
Other Locations
CHU Poitiers
Poitiers, 86021, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Ibrutinib
Study Phase: Phase 1/Phase 2
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Enrollment Status: Terminated
Publish Date: February 09, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 1 Less Clinical Trial

113 Total Publications

Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.
Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.
Journal: Radiology. Imaging cancer
Published: September 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Taillandier's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile